| Zeit | Aktuelle Nachrichten
| | Leser | Medien |
|---|
| 11.02.
| 74.7% Return Seen to Date on SmarTrend Viropharma Call | | 2 | SmarTrend |
| 07.02.
| ViroPharma Says FDA Issues Complete Response Letter Regarding Cinryze | | 32 | AFX News |
| WASHINGTON (dpa-AFX) - ViroPharma Inc. (VPHM) announced the U.S Food and
Drug Administration issued a complete response letter regarding Cinryze (C1
Esterase Inhibitor [Human]) industrial...
Mehr lesen zu:
ViroPharma Says FDA Issues Complete Response Letter Regarding Cinryze | |
| 07.02.
| ViroPharma (VPHM) Says FDA Posted CRL for Cinryze(R) | | - | StreetInsider.com |
| 07.02.
| ViroPharma Provides Update on Industrial Scale Supplement for Cinryze® (C1 Esterase Inhibitor [Human]) | | 9 | PR Newswire |
| EXTON, Pa., Feb. 7, 2012 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced the U.S Food and Drug Administration (FDA) issued a complete response letter regarding...
Mehr lesen zu:
ViroPharma Provides Update on Industrial Scale Supplement for Cinryze® (C1 Esterase Inhibitor [Human]) | |
| 30.01.
| Bearish Moving Average Cross by Viropharma | | 7 | SmarTrend |
| 27.01.
| Viropharma Has Returned 66.2% Since SmarTrend Recommendation | | 3 | SmarTrend |
| 23.01.
| Viropharma Bearish Moving Average Crossover Alert | | 9 | SmarTrend |
| 23.01.
| JP Morgan stuft ViroPharma von overweight auf neutral. | | 78 | BörseGo |
| JP Morgan stuft ViroPharma von overweight auf neutral.
(© BörseGo AG 2012 - Autor: Tobias Krieg, Redakteur)
Mehr lesen zu:
JP Morgan stuft ViroPharma von overweight auf neutral. | |
| 20.01.
| Is ViroPharma's Growth for Real? | | 11 | Motley Fool |
| 16.01.
| ViroPharma receives priority review status for cinryze in Canada | | 8 | Pharma Bus Review |
| 13.01.
| Health Canada Grants ViroPharma Priority Review Status For Its NDS For Cinryz | | 100 | AFX News |
| WASHINGTON (dpa-AFX) - ViroPharma Inc. (VPHM) announced that Health Canada
has granted the company priority review status for its New Drug Submission, or
NDS, for Cinryze.The company noted...
Mehr lesen zu:
Health Canada Grants ViroPharma Priority Review Status For Its NDS For Cinryz | |
| 13.01.
| ViroPharma (VPHM) Gets Priority Review from Health Canada for Cinryze NDS | | 1 | StreetInsider.com |
| 13.01.
| Viropharma Shares Up 59.9% Since SmarTrend's Buy Recommendation | | 1 | SmarTrend |
| 11.01.
| Viropharma Crosses Below its 10-day MA | | 1 | SmarTrend |
| 05.01.
| ViroPharma Provides FY12 Sales Guidance | | 99 | AFX News |
| WASHINGTON (dpa-AFX) - ViroPharma Inc. (VPHM) Thursday said it expects
full-year 2012 worldwide net product sales to be in a range of $600 million to
$660 million.Analysts on a consensus...
Mehr lesen zu:
ViroPharma Provides FY12 Sales Guidance | |
| 05.01.
| ViroPharma Sees 2012 Sales of $600-660M vs $593M Est | | - | Benzinga.com |
| 05.01.
| ViroPharma Provides 2012 Outlook | | 59 | PR Newswire |
| EXTON, Pa., Jan. 5, 2012 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that Vincent Milano, president and chief executive officer of ViroPharma...
Mehr lesen zu:
ViroPharma Provides 2012 Outlook | |
| 05.01.
| Viropharma Has Returned 59.3% Since SmarTrend Recommendation | | - | SmarTrend |
| 05.01.
| Uptrend Call Working As Viropharma Stock Rises 58.2% | | 1 | SmarTrend |
| 05.01.
| 59.3% Return Seen to Date on SmarTrend Viropharma Call | | 1 | SmarTrend |
